137 related articles for article (PubMed ID: 35091172)
1. Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer.
Huang SH; Cao R; Lin QW; Wu SQ; Gao LL; Sun Q; Zhu QH; Zou Y; Xu YG; Wang SP
Eur J Med Chem; 2022 Feb; 230():114116. PubMed ID: 35091172
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
Wang SP; Li Y; Huang SH; Wu SQ; Gao LL; Sun Q; Lin QW; Huang L; Meng LQ; Zou Y; Zhu QH; Xu YG
J Med Chem; 2021 Dec; 64(23):17413-17435. PubMed ID: 34813314
[TBL] [Abstract][Full Text] [Related]
3. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
5. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
6. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
Zhang J; Yang C; Tang P; Chen J; Zhang D; Li Y; Yang G; Liu Y; Zhang Y; Wang Y; Liu J; Ouyang L
J Med Chem; 2022 May; 65(9):6803-6825. PubMed ID: 35442700
[TBL] [Abstract][Full Text] [Related]
8. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
[TBL] [Abstract][Full Text] [Related]
10. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
[TBL] [Abstract][Full Text] [Related]
11. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of quinazolin-4(3
Chang X; Sun D; Shi D; Wang G; Chen Y; Zhang K; Tan H; Liu J; Liu B; Ouyang L
Acta Pharm Sin B; 2021 Jan; 11(1):156-180. PubMed ID: 33532187
[TBL] [Abstract][Full Text] [Related]
13. FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.
Wang SP; Wu SQ; Huang SH; Tang YX; Meng LQ; Liu F; Zhu QH; Xu YG
Cell Death Dis; 2021 Dec; 12(12):1138. PubMed ID: 34880209
[TBL] [Abstract][Full Text] [Related]
14. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
[TBL] [Abstract][Full Text] [Related]
15. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
16. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
17. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
18. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
Xu Y; Wu H; Huang L; Zhai B; Li X; Xu S; Wu X; Zhu Q; Xu Q
Eur J Med Chem; 2022 Jul; 237():114417. PubMed ID: 35504210
[TBL] [Abstract][Full Text] [Related]
19. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
20. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
